Breast cancer is delineated into three distinct molecular subtypes as follows: hormone receptor-positive (HR+), human epidermal growth factor receptor 2 positive (HER2+), and triple-negative breast cancer (TNBC), the latter of which denotes the most clinically aggressive phenotype within the spectrum of breast malignancies (3). This evidence concerns the gene NR4A1 and breast carcinoma.